What are the current guideline‑recommended first‑line and second‑line treatment options for adult patients with newly diagnosed unresectable or metastatic squamous‑cell non‑small cell lung cancer?

Treatment Guidelines for Metastatic Squamous Cell Lung Cancer

For first-line treatment of metastatic squamous cell NSCLC without driver mutations, pembrolizumab combined with carboplatin and paclitaxel (or nab-paclitaxel) is the standard of care for patients with PD-L1 <50% or unknown, while pembrolizumab monotherapy is preferred for PD-L1 ≥50%. 1

First-Line Treatment Algorithm

Step 1: PD-L1 Testing and Performance Status Assessment

• PD-L1 testing is mandatory at diagnosis to guide treatment selection 1
• Assess ECOG performance status (PS 0-1 vs PS 2 vs PS 3-4) 1

Step 2: Treatment Selection Based on PD-L1 Expression

For PD-L1 TPS ≥50% (PS 0-1):

• Preferred: Pembrolizumab monotherapy 1
  • KEYNOTE-024 demonstrated median OS of 30 months vs 14 months with chemotherapy 1
  • This is the standard for high PD-L1 expressors without contraindications to immunotherapy

For PD-L1 TPS <50% or Unknown (PS 0-1):

• Preferred: Pembrolizumab + carboplatin + paclitaxel (or nab-paclitaxel) 1

  • KEYNOTE-407 showed mOS 17.1 vs 11.6 months (HR 0.71) 1
  • This is category 1/2A evidence with consistent benefit across PD-L1 subgroups 1

• Alternative options:

  • Atezolizumab + carboplatin + nab-paclitaxel 1
  • Nivolumab + ipilimumab + 2 cycles platinum-based chemotherapy 1
  • Durvalumab + tremelimumab + platinum-based chemotherapy 1

For PS 2 Patients:

• Carboplatin-based doublet chemotherapy is recommended for eligible patients 1
• Single-agent chemotherapy (gemcitabine, vinorelbine, or docetaxel) for those not suitable for doublet 1
• Immunotherapy should be considered according to standard recommendations if appropriate 1

For PS 3-4 Patients:

• Best supportive care only 1

Step 3: Contraindications to Immunotherapy

If immunotherapy is contraindicated (autoimmune disease, organ transplant, etc.):

• Platinum-based doublet chemotherapy 1
  • Carboplatin + paclitaxel or nab-paclitaxel
  • Note: Pemetrexed is NOT recommended for squamous histology due to lack of efficacy 1

Second-Line Treatment Algorithm

After First-Line Immunotherapy Failure:

Step 1: Confirm Progression

• Patients with PS 0-2 and radiologic/clinical progression should be offered second-line therapy 1

Step 2: Treatment Selection

If progressed on first-line pembrolizumab monotherapy:

• Platinum-based chemotherapy doublet is the recommended second-line option 1
• Carboplatin + paclitaxel or nab-paclitaxel 1

If progressed on first-line chemo-immunotherapy:

• PD-1/PD-L1 inhibitors (nivolumab, pembrolizumab, atezolizumab) are treatment of choice if immunotherapy-naive 1
  • Benefit seen regardless of PD-L1 expression 1
  • Superior survival and tolerability vs docetaxel 1

If not suitable for immunotherapy:

• Docetaxel is the standard chemotherapy option 1
• Ramucirumab + docetaxel for PS 0-2 patients 1
  • This combination improves outcomes after first-line chemotherapy failure

For patients unfit for chemotherapy or immunotherapy:

• Afatinib is a potential option in platinum-pretreated squamous cell carcinoma with unknown EGFR status or EGFR wild-type, PS 0-2 1

Step 3: Treatment Duration

• Continue treatment if disease is controlled and toxicity is acceptable 1

Special Populations

Elderly Patients (≥70 years):

• Immunotherapy should be considered according to standard recommendations 1
  • Subgroup analyses show equivalent efficacy in patients ≥65 years 1
• Carboplatin-based doublet for PS 0-2 with adequate organ function 1
• Single-agent chemotherapy for those not eligible for doublet 1

Critical Pitfalls to Avoid

1. Never use pemetrexed in squamous cell carcinoma - it is restricted to non-squamous histology due to lack of efficacy 1

2. Do not use bevacizumab in squamous histology - safety concerns including hemoptysis risk 1

3. Confirm PD-L1 testing before treatment initiation - this is essential for optimal treatment selection 1

4. Do not continue immunotherapy beyond progression - switch to platinum-based chemotherapy 1

5. Assess performance status carefully - PS 3-4 patients should receive best supportive care only unless molecularly targetable alterations exist 1